Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
peptide
somatostatin analog |
| gptkbp:administeredBy |
injection
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:H01CB02
|
| gptkbp:brand |
gptkb:Sandostatin
|
| gptkbp:CASNumber |
83150-76-9
|
| gptkbp:chemicalFormula |
C49H66N10O10S2
|
| gptkbp:discoveredBy |
gptkb:Sandoz
|
| gptkbp:hasEnantiomer |
D-octreotide
|
| https://www.w3.org/2000/01/rdf-schema#label |
L-octreotide
|
| gptkbp:IUPACName |
(4R,7S,10S,13R,16S,19R)-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]-16-(1H-indol-3-ylmethyl)-7-(4-methoxybenzyl)-10-(2-mercaptoethyl)-13-(2-mercaptoethyl)-19-(1-methylethyl)-2,5,8,11,14,17,20-heptaoxo-1,3,6,9,12,15,18-heptaazacycloicosane-4-carboxamide
|
| gptkbp:molecularWeight |
1019.3 g/mol
|
| gptkbp:target |
somatostatin receptor
|
| gptkbp:usedFor |
gptkb:carcinoid_syndrome
acromegaly VIPoma |
| gptkbp:bfsParent |
gptkb:octreotide
|
| gptkbp:bfsLayer |
6
|